GSK Consumer Healthcare, a division of GlaxoSmithKline PLC, has introduced a new over-the-counter (OTC) allergy relief nasal spray, Flonase Sensimist Allergy Relief. This product, featuring fluticasone furoate at 27.5 mcg per spray, promises enhanced relief for millions of allergy sufferers across the United States.

Breakthrough in Allergy Relief Technology

Flonase Sensimist, employing the innovative MistPro technology, is engineered to offer 24-hour relief from both seasonal and perennial allergy symptoms. These symptoms include nasal congestion, runny or itchy nose, sneezing, and itchy, watery eyes. The product is available for purchase both online and in major retail stores throughout the country, making it easily accessible for those in need.

Enhanced Efficacy and User-Friendly Design

According to Jennifer Nadelson, Senior Brand Manager at Flonase, “GSK Consumer Healthcare has a strong heritage in discovering and developing respiratory products to meet patient needs worldwide. With Flonase Sensimist, we’re proud to offer allergy sufferers an additional product option providing more complete symptom relief in a new, unique, user-friendly device.”

The novel ergonomic design of Flonase Sensimist includes features like being alcohol-free, consistent dosing with each use, a less invasive and shortest nozzle, minimal or no drip, and being scent-free. These features are designed to enhance the user experience, making the spray less obtrusive and more comfortable to use daily.

How Flonase Sensimist Works

Flonase Sensimist works by inhibiting six key inflammatory substances, providing a broad spectrum of action against allergy triggers such as dust, pet dander, mold, and pollen. This is in contrast to most OTC allergy pills, which typically target only histamine, the chemical responsible for many allergy symptoms. GSK Consumer Healthcare claims that Flonase Sensimist is 40% more effective than an unnamed leading non-drowsy allergy pill.

Dr. Clifford Bassett, Founder and Medical Director of Allergy & Asthma Care of New York, emphasized the impact of allergies on quality of life, stating, “For the more than 50 million Americans who suffer from allergies, the burden is more than just a stuffy nose. Uncontrolled allergies have a measurable impact on quality of life, affecting children and adults alike. In my patient population, having a proactive treatment plan in place makes a big difference in managing their allergies.”

Regulatory Approval and Product Line Expansion

Flonase Sensimist was previously available only by prescription but gained OTC status from the U.S. Food and Drug Administration (FDA) in August of the previous year. It joins the comprehensive Flonase product line, which includes Flonase Allergy Relief and Children’s Flonase Allergy Relief, offering a range of options tailored to different needs within the allergy community.

The introduction of Flonase Sensimist represents a significant step forward in over-the-counter allergy care, providing a powerful new option for allergy sufferers. Its broad action against inflammatory substances and user-centric design set a new standard in the category, potentially influencing future developments in allergy treatment products.

  Allergy, allergy relief, Flonase Sensimist, GSK Consumer Healthcare, innovative allergy treatment, OTC nasal spray